Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia
BLyS is involved in CLL biology and its low soluble serum levels related to a shorter time to first treatment (TFT). TACI is a BLyS receptor and can be shed from cells' surface and circulate in soluble form (sTACI). We investigated the impact of serum BLyS and sTACI levels at diagnosis in CLL p...
Main Authors: | Kyrtsonis, Marie-Christine, Sarris, Katerina, Koulieris, Efstathios, Maltezas, Dimitrios, Nikolaou, Eftychia, Angelopoulou, Maria K., Bartzis, Vassiliki, Tzenou, Tatiana, Dimou, Maria, Siakandaris, Mariana P., Viniou, Nora A., Sachanas, Sotirios, Kalpadakis, Christina, Sfikakis, Petros P., Pangalis, Gerassimos A., Panayiotidis, Panayiotis |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138780/ |
Similar Items
-
Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity
by: Kyrtsonis, Marie-Christine, et al.
Published: (2010) -
Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma
by: Koulieris, Efstathios, et al.
Published: (2012) -
The current status of targeting BAFF/BLyS for autoimmune diseases
by: Ramanujam, Meera, et al.
Published: (2004) -
Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia
by: Sarris, Katerina, et al.
Published: (2013) -
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
by: Collins, Christopher E, et al.
Published: (2006)